Association of thyroid disease and intracranial meningiomas: a retrospective analysis with external validation

Background: The scope of comorbid conditions with meningiomas is understudied. There is limited published evidence to date suggesting higher prevalence of thyroid diseases in patients with meningiomas. This retrospective study was designed to evaluate this association.

Methods: The medical records from 584 patients with intracranial meningiomas were reviewed. The prevalence of thyroid disease was calculated as well as odds ratios to compare patient cohorts. Subsequently, the results were externally validated using SlicerDicer data from a second institution’s electronic medical record.

Results: Within the Endeavor Intracranial Meningioma cohort, thyroid disease was found in 196/584 (33.6%): hypothyroidism in 154/584 (26.4%), nodular disease in 34/584 (5.8%), thyroid cancer in 9/584 (1.5%), and hyperthyroidism in 8/584 (1.4%) patients. An additional 9/584 (1.5%) patients had a different thyroid disease or diagnosis. Our external validation with patients only from the second institution yielded significant association of meningioma with thyroid hormone medication use (OR = 6.1), hypothyroidism (OR = 7.5), thyroid cancer (OR = 14.6), hyperthyroidism (OR = 5.9), and thyroid nodules (OR = 10.8). Comparing meningioma patients to patients with glioblastoma yielded a similar association between meningioma and general thyroid disorders (OR = 2.1), thyroid hormone usage (OR = 2.1), hypothyroidism (OR = 1.7), thyroid cancer (OR = 3.1), and thyroid nodules (OR = 7.5). These observations were not confounded by female overrepresentation.

Conclusions: This study confirms thyroid disease, particularly hypothyroidism, to be a common comorbid condition in patients with intracranial meningiomas in two independent datasets. Further research is needed to assess the role of thyroid disorders in the outcomes for patients with meningioma.

Introduction

Meningiomas are the most common type of intracranial neoplasm, accounting for more than 37% of primary intracranial tumors, with an age adjusted incidence rate of 8.56 per 100,000 people (1). Meningiomas arise from the dural lining of the CNS and are graded from 1 to 3 according to the 2021 World Health Organization (WHO) classification system (2). Management of meningiomas includes observation, surgical resection, or radiation therapy; these treatments are effective for most tumors. Systemic therapy plays a limited role in treatment outside of clinical trials (3). Although most tumors are benign, some are malignant, and local invasion can be detrimental to patient quality of life, necessitating treatment (4). Patients who undergo successful surgeries for meningioma have worse 2-year employment rates compared to the general population and the role of comorbidities, such as depression have been implicated in these adverse outcomes (5).

Several genetic, environmental, and metabolic factors play a role in the development of meningiomas. Genetic syndromes such as neurofibromatosis type 2 (NF2), Li-Fraumeni syndrome, and Cowden syndrome are known to increase the risk of these tumors. Furthermore, exposure to radiation therapy significantly increases the risk of meningiomas (6). The diagnosis of meningioma has also been associated with hormonal changes, most notably estrogen and progesterone (7). Indeed, there is an ongoing debate regarding the possible association between hormone replacement therapy (HRT) and development of meningiomas with progesterone use being implicated in meningioma growth (8, 9). However, estrogen HRT has no clear evidence of affecting meningioma growth rates (10). In addition to hormonal changes, metabolic risk factors are being recognized as important drivers of tumor growth. A large retrospective study in an ethnically diverse population found that obesity, diabetes, and hypertension are all associated with meningiomas (11). More research is needed to identify other associations that could provide insight into modifiable risk factors for the development of these relatively common tumors.

Thyroid disease is a comorbid condition in certain patients with meningiomas. Retrospective studies from the US and the UK have previously found associations between meningiomas and thyroid disease (12, 13). Thyroid diseases, particularly hypo- and hyperthyroidism, are relatively common disorders affecting individuals in both iodine-deficient and iodine-replete countries. These conditions are associated with significant morbidity and mortality (14, 15). In the US, overt hypothyroidism (i.e. low T4) is found in 0.3-3.7% of the population, and hyperthyroidism has a prevalence of approximately 0.5% (16). Subclinical hypothyroidism (i.e., high TSH and normal T4) increases with age, is more prevalent in females, and does not necessarily require treatment (17). Thyroid function abnormalities are linked with metabolic dysfunction, another suspected driver of meningioma growth, through several complex molecular mechanisms (18). Thyroid dysfunction may be associated with insulin resistance and metabolic syndrome (19), and obesity has been linked to a higher incidence of meningiomas (20). Based on these observations, we sought to uncover whether there is an association between thyroid disease and intracranial meningiomas in a large dataset of adult patients from our institution. This study is one of the largest analyses of thyroid disease in patients with intracranial meningiomas in the United States.

Materials and methods

The Endeavor Health (formerly NorthShore University HealthSystem) electronic medical record (EMR) entries from 2006 to 2012 were queried for ICD codes of intracranial meningioma. This study was approved by an appropriate institutional review board, and considering this only required retrospective chart review, informed consent was not required or obtained. A total of 584 patients with meningioma were identified after exclusion of alternative diagnoses (e.g., schwannoma). The electronic medical records were reviewed for each patient to identify diagnoses of thyroid disease including hypothyroidism, nodular disease (including multinodular goiters and solitary thyroid nodules), thyroid cancer, hyperthyroidism, and other thyroid disorders (such as thyroid cysts). Prevalence of thyroid disease was calculated in both males and females and were compared by constructing contingency tables to calculate odds ratios and using Fisher’s exact tests. GraphPad Prism (Version 8.4.3) and SPSS (Version 24.0) were used for statistical analysis. P values < 0.05 were considered statistically significant. The results were externally validated using SlicerDicer^® data from the Second Institution’s EMR system to compare meningioma patients to glioblastoma patients (brain tumor control) and patients who underwent thyroid testing between March 2018 and March 2023. An additional variable, thyroid hormone usage, was added in the external validation, as a proxy for clinically significant hypothyroidism, as not all patients diagnosed with hypothyroidism require hormone replacement therapy, such as in cases of subclinical hypothyroidism (21). Thyroid testing was determined by the presence of TSH lab components in SlicerDicer^®. Odds ratios were adjusted for sex and age when comparing meningioma patients with patients who underwent thyroid testing. Age was dichotomized into 18–49 and ≥50 years old based on prior literature suggesting sharp rise in meningioma incidence past age 50 (1).

Results

Patient characteristics are listed in Table 1. In the Endeavor Health System Meningioma Database, there was a high prevalence of thyroid diseases, with the most common being hypothyroidism, found in 154 (26.4%) patients. Nodular thyroid disease was also relatively common in 34 (5.8%) patients. Other thyroid disorders, including thyroid cancer and hyperthyroidism, were less common, each accounting for a small proportion of the thyroid disease burden.

Table 1

Table 1. Patient characteristics (Endeavor Health System Meningioma Database).

External validation of the Endeavor Health data analysis yielded similar findings. 749 patients with meningioma, 1,033 with glioblastoma, and 705,716 patients who received thyroid testing in the Second Institution’s general EMR population were found in SlicerDicer. When comparing the prevalence of thyroid disease between meningioma and glioblastoma patients, the odds ratios for meningioma patients were 2.1 (CI95%, 1.6-2.7) for thyroid hormone usage, 1.7 (CI95%, 1.3-2.2) for hypothyroidism, 3.1 (CI95%, 1.5-6.3) for thyroid cancer, and 7.5 (CI95%, 3.8-14.8) for nodular disease (Table 2; p ≤ 0.001 for all). In contrast, there was no significant difference in the prevalence of hyperthyroidism between meningioma and glioblastoma patients. Comparing thyroid disease in meningioma patients with that of the thyroid tested patient population of the Second Institution yielded an OR of 5.7 (CI95%, 4.8-6.9) for thyroid hormone medication use, 1.4 (CI95%, 1.1-1.7) for hypothyroidism, 3.3 (CI95%, 2.2-4.9) for thyroid cancer, 2.1 (CI95%, 1.3-3.4) for hyperthyroidism, and 4.0 (CI95%, 3.0-5.3) for thyroid nodule (Table 3; p<0.01 for all).

Table 2

Table 2. Comparison of thyroid disease burden between meningioma and glioblastoma patients (external validation cohort).

Table 3

Table 3. Comparison of thyroid disease burden between meningioma patients and the thyroid tested patient population in the external validation cohort.

A subanalysis adjusting for age and sex when comparing meningioma patients to patients who received thyroid testing was performed. For female patients between the ages of 18 and 49, the significant odds ratios for female meningioma patients were 4.5 (CI95%, 1.9-10.4, p=0.003) for thyroid hormone usage and 11.0 (CI95%, 5.2 -23.0, p<0.0001) for nodular disease (Table 4). For females who were at least 50 years old, the statistically significant odds ratios for meningioma patients were 4.8 (CI95%, 3.9-5.9, p<0.0001) for thyroid hormone usage, 2.6 (CI95%, 1.6-4.3, p=0.0005) for thyroid cancer, 2.1 (CI95%, 1.2-3.6, p=0.02) for hyperthyroidism, and 3.7 (CI95%, 2.8-5.0, p<0.0001) for nodular disease (Table 4). Finally, for male patients between the ages of 18 and 49, the only statistically significant odds ratio for male meningioma patients was 10.4 (CI95%, 3.6-29.5, p=0.0009) for thyroid hormone usage, (Table 5). For males who were at least 50 years old, statistically significant odds ratios for meningioma patients were 4.8 (CI95%, 3.9-5.9, p<0.0001) for thyroid hormone usage, 3.4 (CI95%, 1.4-8.3, p=0.02) for thyroid cancer, and 3.4 (CI95%, 1.7-6.9, p=0.003) for nodular disease (Table 5).

Table 4

Table 4. Age and sex adjusted subanalysis comparing thyroid disease burden between female meningioma patients and the female thyroid tested patient population in the external validation cohort.

Table 5

Table 5. Age and sex adjusted subanalysis comparing thyroid disease burden between male meningioma patients and the male thyroid tested patient population in the external validation cohort.

Finally, an analysis of the prevalence of meningiomas in patients with thyroid disease versus thyroid tested patients without thyroid disease was performed. In the female patient population between the ages of 18 and 49 years, the significant meningioma odds ratios were 2.1 (CI95%, 1.6-2.7, p<0.0001) for females with hypothyroidism, 2.7 (CI95%, 1.9-3.9, p<0.0001) for nodular disease, and 2.3 (CI95%, 1.2-4.4, p=0.01) for thyroid cancer (Table 6). For females with thyroid disease aged 50 years or older, the significant meningioma odds ratios were 1.6 (CI95%, 1.4-1.6, p<0.0001) in females with hypothyroidism, 1.7 (CI95%, 1.6-1.9, p<0.0001) for nodular disease, 1.6 (CI95%, 1.3-2.0, p<0.0001) for thyroid cancer, and 0.5 (CI95%, 0.5-0.6, p<0.0001) for thyroid hormone usage (Table 6). For male patients between the ages of 18 and 49 years, the significant meningioma odds ratios were 4.5 (CI95%, 2.9-7.1, p<0.0001) for males with hypothyroidism, 4.1 (CI95%, 1.9-8.9, p<0.0001) for nodular disease, and 3.3 (CI95%, 2.1-5.2, p<0.0001) for thyroid hormone usage (Table 7). For males with thyroid disease aged 50 years or older, the significant meningioma odds ratios were 1.7 (CI95%, 1.5-2.0, p<0.0001) in males with hypothyroidism, 2.0 (CI95%, 1.6-2.5, p<0.0001) for nodular disease, 3.1 (CI95%, 2.2-4.4, p<0.0001) for thyroid cancer, and 0.6 (CI95%, 0.5-0.8, p<0.0001) for thyroid hormone usage (Table 7).

Table 6

Table 6. Age and sex adjusted subanalysis comparing meningioma disease burden between female thyroid disease patients and the female thyroid tested patient population in the external validation cohort.

Table 7

Table 7. Age and sex adjusted subanalysis comparing meningioma disease burden between male thyroid disease patients and the male thyroid tested patient population in the external validation cohort.

Discussion

The etiology and pathogenesis of meningiomas and potential overlaps with thyroid dysfunction remain largely unknown (22). In this retrospective study with external validation, we show that thyroid disease may be associated with intracranial meningiomas, supporting previous research by others (11, 12). Within the Endeavor HealthSystem Intracranial Meningioma cohort, we also found that thyroid disease was more common in females than males, however this is expected given the previously established individual associations between the female sex, thyroid disease, and meningioma (Supplementary Table 1) (11, 15). After adjustment for age and sex in the External Validation cohort, meningioma patients did not have higher odds of having hypothyroidism; however, they were significantly more likely to be using thyroid hormone replacement therapy. This suggests that patients with meningiomas may be more likely to experience clinically significant hypothyroidism requiring treatment.

Thyroid hormones are necessary for normal brain development and cross the blood-brain barrier by binding to transmembrane transporters (23, 24). Mechanistically, it is unclear whether or how thyroid function might affect meningioma development or growth. However, hypothyroidism (the most commonly identified thyroid disorder in our cohort) is associated with metabolic dysfunction and possibly obesity, both risk factors for the development of meningiomas and other neoplasms (25). It is plausible that thyroid dysfunction may contribute to meningioma pathogenesis through adverse effects on metabolism, a mechanism previously proposed by Seliger et al., who found in their matched case-control retrospective analysis that both obesity and arterial hypertension, core features of metabolic syndrome, were associated with an increased risk of meningioma (26). These findings have been substantiated by numerous studies, which have consistently linked adiposity with elevated meningioma risk (7, 27–31).

Further potential mechanisms of thyroid dysfunction and meningioma risk may involve the interplay between obesity, elevated serum insulin (32) and insulin-like growth factor levels (33), and the excess production of estrogens from adipose tissue (34), all of which may contribute to meningioma risk, especially in women (35, 36). Chronic inflammation, impaired immune function, and increased oxidative stress, which are common in metabolic syndrome, may also play a role in meningioma tumorigenesis (37). Interestingly, while speculation exists that elevated insulin signaling may promote meningioma development, the literature remains mixed, as some studies have found positive, null, and negative associations between diabetes and meningioma risk (26, 38–40). Overall, while the existing literature on the topic of obesity, abnormal insulin signaling, and their association with increased meningioma risk may not be conclusive, our findings in conjunction with prior literature warrant further investigation into the mechanistic link between thyroid dysfunction, metabolic dysfunction, and meningioma development. A better understanding of these mechanisms may shed light on modifiable risk factors and inform future preventative or therapeutic strategies for this disease.

Considering that intracranial tumors are often treated with cranial irradiation, one possible confounding mechanism of thyroid dysfunction in meningioma patients is secondary to treatment, which has been previously suggested (41, 42). Our database did not specifically identify the diagnosis of central (secondary) hypothyroidism, and it is possible that a subset of hypothyroid patients had hypothyroidism due to pituitary dysfunction. Brain irradiation, especially, is a well-known cause of pituitary dysfunction (42). Alternatively, Schneider et al. suggested that patients can develop hypopituitarism as a result of neurosurgery alone (43). In this study, this complication occurred more frequently in patients who underwent neurosurgery compared to those who only received chemotherapy or radiotherapy, regardless of whether the tumor was centrally or non-centrally located (43). This finding suggests that brain trauma secondary to surgical treatment may play a pivotal role in the development of pituitary dysfunction (42). However, in this study, the higher prevalence of thyroid disorders in meningioma relative to glioblastoma is unlikely to be driven by interventional confounders. This is due to differences in standard-of-care between the populations: brain radiotherapy and chemotherapy are utilized nearly universally in glioblastoma but used in only a small fraction of meningiomas cases (44). It does remain possible that development of treatment-induced thyroid dysfunction is diagnosed at a lower rate in glioblastoma due to the shorter survival in this patient cohort. Additionally, these interventional mechanisms do not address the other thyroid issues possibly associated with meningiomas, such as hyperthyroidism, thyroid cancer, and thyroid nodules. Although strong individual associations exist between female sex, age, and both thyroid disorders and meningiomas (45), controlling for sex and age in our stratified analyses still uncovered higher odds ratios of thyroid disorders among meningioma patients relative to patients who underwent thyroid testing. This demonstrates that the observed relationship remains independent of sex and age as confounding variables. Interestingly, while this study mainly served to analyze the prevalence of thyroid disease in meningioma patients, similar associations were observed when analyzing the reverse, the prevalence of meningiomas in patients with thyroid disease, with significant associations found in all subgroups except for patients with hyperthyroidism, young males with thyroid cancer, and young females taking thyroid hormones. Of note, we observed a lower prevalence of meningiomas in both older male and female patients taking thyroid hormones, which may seem to contradict our earlier finding of increased thyroid hormone usage in patients with meningiomas when compared to the thyroid tested general population. However, it is important to note that these observations are fundamentally different, as the former examines the proportion of thyroid hormone users among meningioma patients, while the latter assesses the proportion of meningioma diagnoses among thyroid hormone users. These findings may reflect differing baseline risks, treatment behaviors, or ascertainment patterns with these subpopulations. Nevertheless, this study notes bidirectional associations between thyroid disease and meningiomas, and the unclear nature of these associations highlights the need for longitudinal analyses to assess causality and temporal relationships.

One potential source of concern in this study is detection bias, as meningioma patients may have been more likely to receive testing for thyroid function. However, our control population was limited to patients who received thyroid testing from the Second Institution, consequently minimizing this source of bias. Thus, overall, our findings suggest the potential existence of other unexplored mechanisms linking thyroid disorders to meningiomas that may be of clinical significance. Particularly, given the higher proportion of patients with thyroid hormone replacement (clinically significant hypothyroidism) in the meningioma cohort, thyroid screening could potentially be considered during the work up for meningioma, however, further research is required to clarify the nature of this association and determine whether formal thyroid screening guidelines for meningioma patients are justified. Additionally, the role of comorbidities, such as depression in adverse postoperative employment outcomes for meningioma patients has been described before (5), and thyroid dysfunction is potentially another, modifiable risk factor.

Limitations

Although this study suggests an interesting link between thyroid disease and meningiomas, there are limitations that should be considered. Firstly, the study is retrospective in nature, making it difficult to establish a causal link between thyroid dysfunction and meningiomas. The study is also limited as the Endeavor Health analysis does not include a control group. However, our external validation of the results using the Second Institution’s EMR SlicerDicer data mitigates this limitation as it compares thyroid disease prevalence in meningioma patients and the thyroid tested patient population. The SlicerDicer data also strengthens the reproducibility of this study as it involves an independent cohort of patients, and the use of a brain tumor control cohort allows us to reduce the probability of confounding by intracranial interventions. Another limitation of this study is that the hypothyroidism diagnosis may include both primary and secondary hypothyroidism, which may be present in patients with meningiomas in the sellar region. Potential confounding variables include obesity. However, our data is in line with previous retrospective studies. Further research is needed to explore the potential role of thyroid function in meningioma pathogenesis, evaluating possible molecular drivers as well as effects on tumor volume and growth rate. Prospective studies tracking thyroid function over time may shed light on the importance of endocrine function on meningioma growth and development.

Conclusions

Thyroid dysfunction is common in patients with intracranial meningiomas. Hypothyroidism is the most common thyroid disorder in this cohort. Although a mechanistic link has not been established, there is growing evidence suggesting an interplay between thyroid function and the development of meningiomas and other intracranial tumors. Future studies are needed to establish the impact of thyroid disease on meningioma outcomes.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Johns Hopkins Medicine Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

MS-G: Writing – review & editing, Formal analysis, Writing – original draft, Data curation, Methodology, Investigation. JB: Formal analysis, Data curation, Writing – review & editing, Methodology, Writing – original draft. CY: Writing – review & editing. AW: Writing – review & editing. LD: Writing – review & editing. MW: Writing – review & editing. CT: Writing – review & editing. RS: Writing – review & editing. DM: Writing – review & editing. DK: Supervision, Writing – review & editing, Methodology, Investigation, Conceptualization, Data curation, Resources, Formal analysis. RM: Conceptualization, Writing – review & editing, Supervision.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1635097/full#supplementary-material

References

1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro-Oncology. (2019) 21:v1–v100. doi: 10.1093/neuonc/noz150

PubMed Abstract | Crossref Full Text | Google Scholar

2. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. (2021) 23:1231–51. doi: 10.1093/neuonc/noab106

PubMed Abstract | Crossref Full Text | Google Scholar

3. Apra C, Peyre M, and Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. (2018) 18:241–9. doi: 10.1080/14737175.2018.1429920

PubMed Abstract | Crossref Full Text | Google Scholar

4. Karsy M, Jensen MR, Guan J, Ravindra VM, Bisson EF, Couldwell WT, et al. EQ-5D quality-of-life analysis and cost-effectiveness after skull base meningioma resection. Neurosurgery. (2019) 85:E543–E552. doi: 10.1093/neuros/nyz040

PubMed Abstract | Crossref Full Text | Google Scholar

5. Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV, et al. An overview of meningiomas. Future Oncol. (2018) 14:2161–77. doi: 10.2217/fon-2018-0006

PubMed Abstract | Crossref Full Text | Google Scholar

6. Jhawar BS, Fuchs CS, Colditz GA, and Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. (2003) 99:848–53. doi: 10.3171/jns.2003.99.5.0848

PubMed Abstract | Crossref Full Text | Google Scholar

7. Shu X, Jiang Y, Wen T, Lu S, Yao L, and Meng F. Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching. Asia-Pacific J Clin Oncol. (2019) 15:e147–e153. doi: 10.1111/ajco.13138

PubMed Abstract | Crossref Full Text | Google Scholar

8. Weill A, Nguyen P, Labidi M, Cadier B, Passeri T, Duranteau L, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. (2021) 372:n37. doi: 10.1136/bmj.n37

PubMed Abstract | Crossref Full Text | Google Scholar

9. Dresser L, Yuen CA, Wilmington A, Walker M, Vogel TJ, Merrell R, et al. Estrogen hormone replacement therapy in incidental intracranial meningioma: a growth-rate analysis. Sci Rep. (2020) 10:17960. doi: 10.1038/s41598-020-74344-x

PubMed Abstract | Crossref Full Text | Google Scholar

10. Cea-Soriano L, Wallander M-A, and Rodríguez LAG. Epidemiology of meningioma in the United Kingdom. Neuroepidemiology. (2012) 39:27–34. doi: 10.1159/000338081

PubMed Abstract | Crossref Full Text | Google Scholar

11. Lee E, Grutsch J, Persky V, Glick R, Mendes J, and Davis F. Association of meningioma with reproductive factors. Int J Cancer. (2006) 119:1152–7. doi: 10.1002/ijc.21950

PubMed Abstract | Crossref Full Text | Google Scholar

12. Thvilum M, Brandt F, Almind D, Christensen K, Hegedüs L, and Brix TH. Excess mortality in patients diagnosed with hypothyroidism: A nationwide cohort study of singletons and twins. J Clin Endocrinol Metab. (2013) 98:1069–75. doi: 10.1210/jc.2012-3375

PubMed Abstract | Crossref Full Text | Google Scholar

13. Osman F, Gammage MD, and Franklyn JA. Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid. (2002) 12:483–7. doi: 10.1089/105072502760143854

PubMed Abstract | Crossref Full Text | Google Scholar

14. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. (2018) 14:301–16. doi: 10.1038/nrendo.2018.18

PubMed Abstract | Crossref Full Text | Google Scholar

15. Peeters RP. Subclinical hypothyroidism. New Engl J Med. (2017) 376:2556–65. doi: 10.1056/NEJMcp1611144

PubMed Abstract | Crossref Full Text | Google Scholar

16. Mullur R, Liu Y-Y, and Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. (2014) 94:355–82. doi: 10.1152/physrev.00030.2013

PubMed Abstract | Crossref Full Text | Google Scholar

17. Mehran L, Amouzegar A, and Azizi F. Thyroid disease and the metabolic syndrome. Curr Opin Endocrinol Diabetes Obes. (2019) 26:256–65. doi: 10.1097/MED.0000000000000500

PubMed Abstract | Crossref Full Text | Google Scholar

18. Muskens IS, Wu AH, Porcel J, Cheng I, Marchand LL, Wiemels JL, et al. Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. Neuro Oncol. (2019) 21:498–507. doi: 10.1093/neuonc/noz005

PubMed Abstract | Crossref Full Text | Google Scholar

19. Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, et al. Epidemiology of meningiomas. Neurochirurgie. (2018) 64:5–14. doi: 10.1016/j.neuchi.2014.05.006

PubMed Abstract | Crossref Full Text | Google Scholar

20. Liu Y-Y and Brent GA. Thyroid hormone and the brain: Mechanisms of action in development and role in protection and promotion of recovery after brain injury. Pharmacol Ther. (2018) 186:176–85. doi: 10.1016/j.pharmthera.2018.01.007

PubMed Abstract | Crossref Full Text | Google Scholar

21. Burgos N, Toloza FJK, Singh Ospina NM, Brito JP, Salloum RG, Hassett LC, et al. Clinical outcomes after discontinuation of thyroid hormone replacement: A systematic review and meta-analysis. Thyroid. (2021) 31:740–51. doi: 10.1089/thy.2020.0679

PubMed Abstract | Crossref Full Text | Google Scholar

22. Bernal J, Guadaño-Ferraz A, and Morte B. Thyroid hormone transporters—functions and clinical implications. Nat Rev Endocrinol. (2015) 11:406–17. doi: 10.1038/nrendo.2015.66

PubMed Abstract | Crossref Full Text | Google Scholar

23. Avgerinos KI, Spyrou N, Mantzoros CS, and Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. (2019) 92:121–35. doi: 10.1016/j.metabol.2018.11.001

PubMed Abstract | Crossref Full Text | Google Scholar

24. Constine LS, Rubin P, Woolf PD, Doane K, and Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system Malignancies. J Clin Oncol. (1987) 5:1841–51. doi: 10.1200/JCO.1987.5.11.1841

PubMed Abstract | Crossref Full Text | Google Scholar

25. Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U, et al. Metabolic syndrome in relation to risk of meningioma. Oncotarget. (2017) 8:2284–92. doi: 10.18632/oncotarget.13667

PubMed Abstract | Crossref Full Text | Google Scholar

26. Niedermaier T, Behrens G, Schmid D, Schlecht I, Fischer B, and Leitzmann MF. Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology. (2015) 85:1342–50. doi: 10.1212/WNL.0000000000002020

PubMed Abstract | Crossref Full Text | Google Scholar

27. Benson VS, Kirichek O, Beral V, and Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer. (2015) 136:2369–77. doi: 10.1002/ijc.29274

PubMed Abstract | Crossref Full Text | Google Scholar

28. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer. (2013) 109:289–94. doi: 10.1038/bjc.2013.304

PubMed Abstract | Crossref Full Text | Google Scholar

29. Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, and Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer. (2006) 6:152. doi: 10.1186/1471-2407-6-152

PubMed Abstract | Crossref Full Text | Google Scholar

30. Schildkraut JM, Calvocoressi L, Wang F, Wrensch M, Bondy ML, Wiemels JL, et al. Endogenous and exogenous hormone exposure and the risk of meningioma in men. J Neurosurg. (2014) 120:820–6. doi: 10.3171/2013.12.JNS131170

PubMed Abstract | Crossref Full Text | Google Scholar

31. Strain G, Zumoff B, Rosner W, and Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab. (1994) 79:1173–6. doi: 10.1210/jcem.79.4.7962291

PubMed Abstract | Crossref Full Text | Google Scholar

32. Schneider HJ, Saller B, Klotsche J, März W, Erwa W, Wittchen HU, et al. Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol. (2006) 154:699–706. doi: 10.1530/eje.1.02131

PubMed Abstract | Crossref Full Text | Google Scholar

33. Rohrmann S, Shiels MS, Lopez DS, Rifai N, Nelson WG, Kanarek N, et al. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control. (2011) 22:1141–51. doi: 10.1007/s10552-011-9790-z

PubMed Abstract | Crossref Full Text | Google Scholar

34. Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, and Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One. (2013) 8:e83261. doi: 10.1371/journal.pone.0083261

PubMed Abstract | Crossref Full Text | Google Scholar

35. Glick RP, Gettleman R, Patel K, Lakshman R, and Tsibris JC. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects. Neurosurgery. (1989) 24:791–7. doi: 10.1227/00006123-198906000-00001

PubMed Abstract | Crossref Full Text | Google Scholar

36. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. (2011) 12:3117–32. doi: 10.3390/ijms12053117

PubMed Abstract | Crossref Full Text | Google Scholar

37. Schneider B, Pülhorn H, Röhrig B, and Rainov NG. Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev. (2005) 29:440–7. doi: 10.1016/j.cdp.2005.07.002

PubMed Abstract | Crossref Full Text | Google Scholar

38. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer. (1999) 82:155–60. doi: 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P

PubMed Abstract | Crossref Full Text | Google Scholar

39. Bernardo BM, Orellana RC, Weisband YL, Hammar N, Walldius G, Malmstrom H, et al. Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality. Br J Cancer. (2016) 115:108–14. doi: 10.1038/bjc.2016.157

PubMed Abstract | Crossref Full Text | Google Scholar

40. Faghih-Jouybari M, Naderi S, Mashayekhi S, Padeganeh T, and Abdollahzade S. Hypothyroidism among patients with glioblastoma multiforme. Iran J Neurol. (2018) 17:149–51.

PubMed Abstract | Google Scholar

41. Schneider HJ, Rovere S, Corneli G, Croce CG, Gasco V, Rudà R, et al. Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. Eur J Endocrinol. (2006) 155:559–66. doi: 10.1530/eje.1.02272

PubMed Abstract | Crossref Full Text | Google Scholar

42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): central nervous system cancers (2024). National Comprehensive Cancer Network. NCCN. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (Accessed November 22, 2024).

Google Scholar

43. Garcia CR, Slone SA, Chau M, Neltner JH, Pittman T, and Villano JL. Initial management of meningiomas: Analysis of the National Cancer Database. Cancer Epidemiol. (2019) 60:16–22. doi: 10.1016/j.canep.2019.02.018

PubMed Abstract | Crossref Full Text | Google Scholar

44. Mulder JE. Thyroid disease in women. Med Clin North Am. (1998) 82:103–25. doi: 10.1016/S0025-7125(05)70596-4

PubMed Abstract | Crossref Full Text | Google Scholar

45. Wiemels J, Wrensch M, and Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. (2010) 99:307–14. doi: 10.1007/s11060-010-0386-3

PubMed Abstract | Crossref Full Text | Google Scholar